Jonathan Rockoff is the Health Business editor at The Wall Street Journal, managing a team that reports on pharmaceutical and biotechnology companies, health insurers and hospitals. During the ...

Confusion over the FDA delay in granting full approval to Novavax’s Covid-19 vaccine deepened over the weekend, with possible ...

The FDA has discussed with vaccine-maker Novavax the need for an additional trial of its COVID-19 vaccine as a post-approval commitment ...

The Cleburne Railroaders hosted their first taste of baseball at La Moderna Field with exhibition games between the Charros de Jalisco and the Pasta City All-Stars. Among the roster of all-stars ...

With that in mind, let's consider two stocks down 17% and 36%, respectively, this year that are worth investing in right now: ...

Nearly a year and a half after Covid vaccines became available to adults in the U.S., the FDA has authorized two vaccines for ...

In the latest trading session, Moderna (MRNA) closed at $27.19, marking a -0.75% move from the previous day. This change lagged the S&P 500's 0.74% gain on the day. On the other hand, the Dow ...

Federal regulators have asked Novavax to complete an additional clinical trial on its COVID-19 vaccine after previously ...

On Tuesday, the U.S. Department of Health and Human Services announced that the government will invest $176 million in ...

If you’re on the fence about investing in Moderna, Inc. or Vericel Corporation because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

If you’re on the fence about investing in Moderna, Inc. or Alvotech because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision. Read on to ...

US stocks skyrocketed higher after President Donald Trump announced that he authorized a 90-day pause on the “reciprocal” tariffs that had gone into effect Wednesday, with the exception of ...